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Abstract
Background:  Permeability of the blood-brain barrier is one of the factors determining the
bioavailability of therapeutic drugs and resistance to chemically different antiepileptic drugs is a
consequence of decreased intracerebral accumulation. The ABC transporters, particularly P-
glycoprotein, are known to play a role in antiepileptic drug extrusion, but are not by themselves
sufficient to fully explain the phenomenon of drug-resistant epilepsy. Proteomic analyses of
membrane protein differentially expressed in epileptic foci brain tissue revealed the frequently
increased expression of RLIP76/RALBP1, a recently described non-ABC multi-specific transporter.
Because of a significant overlap in substrates between P-glycoprotein and RLIP76, present studies
were carried out to determine the potential role of RLIP76 in AED transport in the brain.
Results: RLIP76 was expressed in brain tissue, preferentially in the lumenal surface of endothelial
cell membranes. The expression was most prominent in blood brain barrier tissue from excised
epileptic foci. Saturable, energy-dependent, anti-gradient transport of both phenytoin and
carbamazepine were demonstrated using recombinant RLIP76 reconstituted into artificial
membrane liposomes. Immunotitration studies of transport activity in crude membrane vesicles
prepared from whole-brain tissue endothelium showed that RLIP76 represented the dominant
transport mechanism for both drugs. RLIP76-/- knockout mice exhibited dramatic toxicity upon
phenytoin administration due to decreased drug extrusion mechanisms at the blood-brain barrier.
Conclusion: We conclude that RLIP76 is the predominant transporter of AED in the blood brain
barrier, and that it may be a transporter involved in mechanisms of drug-resistant epilepsy.
Background
Each year approximately 160,000 persons are diagnosed
with epilepsy, and about 10,000 of these individual
develop drug-resistant epilepsy [1]. The causes of drug-
resistant epilepsy are numerous, many due to ontogenic
abnormalities in brain maturation, severe brain injuries
with resultant irreversible changes to cerebral neuroglial
organization and inhibitory neuron function, kindling
phenomenon, seizure-induced disturbances of oxygen
supply, as well as acquired (or hereditary) changes in
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transporter proteins of the blood-brain barrier which
function in the efflux of anti-epileptic drugs (AEDs) from
the brain. The latter mechanisms have been the focus of
intense efforts to develop new rationally designed AEDs
that could bypass these transport mechanisms. Unfortu-
nately, the identity of the multiple transport mechanisms
of the blood brain barrier, and the individual role of each
in mediating drug-resistant epilepsy is as yet incompletely
defined.
The ABC-family transporters have been the subject of con-
siderable interest in the mechanisms of drug-resistant epi-
lepsy [2,3]. The prototypical ABC transporter, P-
glycoprotein (Pgp, MDR1, or mdr1 gene product), as well
as MRP2, and BCRP are expressed in the blood-brain bar-
rier [2]. Endothelial expression of Pgp has been demon-
strated, and the role of Pgp in regulating brain drug-
concentrations has been established in knockout mouse
studies [4]. These studies evaluated the transport of a
number of centrally acting drugs including antipsychotics,
ant emetics, and natural product antineoplastic agents.
The only AED examined, phenytoin (PHE), appeared to
be a weak substrate of Pgp in intact cell transport experi-
ments. Carbamazepine (CBZ) has been found not to
inhibit Pgp mediated transport, thus would be a poor sub-
strate [5]. Recently, studies examining the ability of AED
to competitively inhibit the transport activity of Pgp have
found little effect of AEDs on Pgp activity, and then only
at concentrations well above clinically achieved therapeu-
tic levels [6]. Although Pgp appears to mediate some
minor transport activity towards most CNS active agent,
the greatest CSF/plasma ratios (6.6–17 fold) were seen
with antipsychotics and antiemetics rather than AEDs, evi-
dence has been presented which suggests that there have
been no reports directly demonstrating transport of any
AED by Pgp in an isolated system [7].
In epileptic patients, expression of MDR1 has a complex
pattern that does not directly support a significant phar-
macokinetic role for MDR1 in human epilepsy since
MDR1 expression was found in both blood-brain barrier
and parenchymal cells in epileptic brain [8-10]. This is
based on the possibility that expression of MDR1 in glia
may actually favor drug interactions with neuronal by
reducing the accumulation of drug in the glial syncitium.
Conversely, parenchymal expression may shift concentra-
tions in the extracellular and intracellular space or may
mediate compartmentalization, and thus may reduce con-
centrations of antiepileptic drugs at their target sites. The
fact that MDR1 may not be a crucial determinant for mul-
tiple drug resistance to antiepileptic drugs has been
recently challenged in a number of reports [11-13]. Other
ABC-transporters, most notably MRP2 and BCRP have
also been localized to the blood-brain barrier, but simi-
larly, direct evidence for the ability of these proteins to
transport AEDs in isolated systems has been lacking.
Because of the lack of information regarding the kinetic
parameters of transport, the relative contributions of dif-
ferent ABC transporters in mediating drug-resistant epi-
lepsy remains unknown and a major impediment to
development of novel targeted anti-epileptic agents.
We have recently described a novel non-ABC mutispecific
transporter, RLIP76, a multifunctional modular protein
found ubiquitously from Drosophila to humans [14-17].
It is encoded in humans on chromosome 18p11.3 by a
gene with 11 exons and 9 introns. RLIP76 is a 76 kDa pro-
tein product of this gene, but splice-variants including a
67 kDa peptide and longer 80 or 102 kDa peptide, cyto-
centrin have been identified [18]. RLIP76 was cloned as a
Ral-binding protein and predicted to be an effector
involved in regulation of membrane plasticity, move-
ment, and endocytosis [17,19-21]. RLIP76 was identified
as a highly active efflux mechanisms for removing glutath-
ione-electrophile conjugate (GS-E, i.e. LTC4) from cells
[22]. In addition to GS-E, the exceptionally broad sub-
strate specificity of RLIP76 extends to Pgp substrates
including anthracycline and vinca alkaloids, towards
which it mediates resistance [23-27]. Studies on pro-
teomic screening of epileptic foci led to the identification
of RLIP76 as being frequently up-regulated. Present stud-
ies were carried out to examine the role of RLIP76 in AED
transport in the blood-brain barrier.
Results and discussion
RLIP76 was expressed in all normal human tissues exam-
ined, more prominently in breast, heart, liver and erythro-
cytes, and less so in colon and brain parenchyma (Fig. 1a,
b &1c). Significant expression was seen in malignant
human cell lines including the PC-3 human prostate can-
cer and H1299 human non-small cell lung cancer cell
lines. Whereas RLIP76 was barely detectable in normal
brain parenchyma or vessels, blood vessels from epileptic
patients has a markedly increased expression of RLIP76
(Fig. 1b &1c).
Epileptic brain sections obtained from multiple drug
resistant patients also revealed substantial differences
compared to non-epileptic brain. By immunocytochemi-
cal analysis, we discovered widespread RLIP76 expression
in the cerebral vasculature from epileptic brain. We used
double label immunofluorescence to reveal that RLIP76
co-localized with the multidrug resistance transporter P-
glycoprotein (MDR1) but not with NeuN or GFAP (Fig.
1d, e, f, and 1h). However, while MDR1 was expressed in
both parenchymal and endothelial cells [8,9], RLIP76
immunoreactivity was limited to the vasculature. No over-
lapping expression of RLIP76 was observed in GFAP pos-
itive astroglia (Fig. 1e) or NeuN positive neurons (Fig.
1d). By confocal analysis, RLIP76 expression was found inBMC Neuroscience 2005, 6:61 http://www.biomedcentral.com/1471-2202/6/61
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Human expression of RLIP76 Figure 1
Human expression of RLIP76. A) Immunocytochemical detection was performed on tissue arrays with histological sec-
tions from normal human tissue. RLIP76 expression was virtually absent from normal brain autopsies; both gray and white mat-
ter were analyzed; cumulative data for brain and blood tissue are presented in b). RLIP76 immunoreactivity was observed in 
breast lobules of primary duct elements, in cardiac myocytes and liver sinusoids. No expression was found in colon tissue. 
Intense immunoreactivity was present in cell lines of tumor origin. Bars indicate 60 µm with the exception of the cell culture 
data, where the bars reflect 10 µm. The inset in a) shows a negative control of a brain section incubated with secondary but 
not primary antibodies. B) Cerebrovascular expression of RLIP76 in epileptic brain. Blood vessels from multiple drug 
resistant epileptic brain were characterized by high levels of RLIP76 expression. Both vascular and intravascular cells were 
RLIP76 immunopositive. RLIP76-positive intravascular cells were anucleated and did not react with the nuclear stain DAPI (in 
blue, C). Note that erythrocytes were found to be RLIP76 immunopositive in both normal and epileptic tissue. RLIP76 is 
expressed exclusively in epileptic endothelial cells and does not localize to glia or neurons. D) NeuN expression 
is segregated from RLIP76 immunoreactivity, which is limited to cortical vessels. E) Widespread GFAP immunoreactivity in 
epileptic brain does not co-localize with RLIP76 (in green). Both large (arrow) and capillary-size (asterisk) vessels express 
RLIP76. Note the large region of GFAP positive reactive gliosis (limited by a dotted line) characterized by the absence of RLIP76 
expression. F) MDR1 and RLIP76 co-localize in "epileptic" blood vessels but MDR1 expression extends to paren-
chymal cells. Three large pial vessels are shown to demonstrate the predominant vascular expression of RLIP76. Note that 
MDR1 expression was more predominant in parenchymal glia. G-H) High power demonstration of endothelial co-
expression of RLIP76/MDR1. Note that MDR1 expression co-localized with RLIP76 expressed at the lumenal surface, while 
MDR1 expression was also observed in RLIP76-negative ablumenal structures reflecting glial endfeet (arrowheads in H). We 
studied a total of 41 patients, including samples from 6 autopsies. The average age of the patients was 32 ± 18 years, range 3 
months – 59 years old. No data are available on the autopsy material, besides the fact that these were adults of either sex. The 
non-epileptic patients were either undergoing surgery for aneurysm clipping or to remove arteriovenous or other vascular 
malformations. None of these patients had seizures prior to surgery or received antiepileptic drug treatment. The surgical epi-
leptic patients studied were resistant to the following drugs: CBZ = 61%; PHE = 77%; Pentobarbital = 55%; Tompiramate = 
50%; valproic acid = 44%; other AEDs, less than 5%. Most patients were resistant to > two drugs; 1 patients (a 3 months old 
infant) did not undergo any drug treatment, while another patient (8 month old) attempted ketogenic diet treatment).BMC Neuroscience 2005, 6:61 http://www.biomedcentral.com/1471-2202/6/61
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capillary endothelial cells, penetrating pial vessels, and
larger (>100 µm) vessels (Fig. 1d, e, and 1f). In capillary
endothelial cells, MDR1 expression was both lumenal
(endothelial) and abluminal (glial endfeet), whereas
RLIP76 expression appeared to be predominantly lume-
nal and did not co-localize with GFAP immunoreactivity
(Fig. 1g and 1h). Additional studies are needed to confirm
this finding.
Since the predominant endothelial localization of RLIP76
suggested a strategic role in determining multiple drug
resistance to antiepileptic drugs, we tested the ability of
RLIP76 to extrude the classic antiepileptic drug PHE [28]
(Fig. 2). This was examined in an isolated system consist-
ing of asolectin-cholesterol artificial liposomes reconsti-
tuted in the presence of purified human RLIP76 [23,24].
Uptake of PHE by liposomes with RLIP76 or without
(control) was examined in the presence or absence of ATP.
Presence of ATP in the transport medium increased the
uptake of 14C-PHE by RLIP76-liposomes in a dose
dependent fashion, whereas ATP had no effect on uptake
by control liposomes (Fig. 2a). We also determined that
the intra-vesicular concentration of PHE in control lipo-
somes with or without ATP and in RLIP76 liposomes
without ATP were near the extra-vesicular drug-concentra-
tion (1 µM), while RLIP76-liposomes in the presence of
ATP had intra-vesicular PHE concentrations of 5.7 µM,
demonstrating that in the presence of ATP, RLIP76 lipo-
somes are able to concentrate PHE against a gradient, the
hallmark of active transport.
Similar findings were obtained when investigating ATP-
dependent transport of another classic antiepileptic drug
carbamazepine (CBZ). While it is commonly believed that
PHE is an MDR1 substrate, uncertainty exists on CBZ
extrusion by MDR1 [5,29]. Uptake of PHE or CBZ by
inside-out vesicles was a time dependent process with
kinetics consistent with a single compartment filling
model (Fig. 2b), and the initial velocity of transport could
be reasonably estimated by measuring uptake at 2 min
after addition of ATP. Both antiepileptic drugs (AED) were
transported by RLIP76 liposomes (Fig. 2d) Initial velocity
kinetics performed with varying either substrate (ATP or
CBZ/PHE), while holding the other constant showed that
the Km for PHE and CBZ was 0.43 and 0.25 µM respec-
tively (Fig. 2e) and for ATP 1.33 mM (PHE) and 3.3 mM
(CBZ) (Fig. 2c).
We then compared function and levels of expression of
RLIP76 in non-epileptic brain resected during cerebrovas-
cular surgery unrelated to epileptic pathology or drug
resistance vs. epileptic brain. Expression of RLIP76 was
determined by Western blot of tissue blocks and mRNA
analysis in isolated and cultured brain microvascular
endothelial cells (Fig. 2f–h). We found that RLIP76
mRNA expression was greater in epileptic brain or
endothelial cells isolated from the same tissue and that
RLIP76 protein levels correlated with PHE transport activ-
ity measured in inside-out vesicles prepared from brain
tissue (Fig. 2h).
Functional RLIP76 expression and AED transport activity
were further studied in freshly collected human brain
samples from epileptic patients. To determine the relative
contribution of RLIP76 toward total PHE/CBZ efflux
capacity, we examined drug transport in the absence or
presence of anti-RLIP76 antibodies [23] in crude mem-
brane vesicles prepared from freshly collected human epi-
leptic brain tissue (n = 8; Fig. 3a, b). Anti-RLIP76
inhibited total transport of PHE and CBZ by 64 ± 6 and 74
± 1.82% respectively (p < 0.01). When we repeated the
same experiments with anti-MDR1 antibodies, we found
inhibition by 21 ± 9 (PHE) and 13 ± 1.86 (CBZ) %; expo-
sure to both antibodies resulted in a cumulative inhibi-
tion. Interestingly, the amount of PHE extrusion by MDR1
determined by antibody-mediated inactivation was com-
parable to that described in a previous study after pharma-
cological blockade by XR9576, a specific MDR1 blocker
[30]. These findings indicated that RLIP76 is the predom-
inant AED transporter in brain tissue.
For the above experiments, we directly obtained vesicles
from acutely isolated cortical samples. Under these condi-
tions, culture artifacts are avoided but the individual con-
tribution of a given cell type remains undetectable. To
determine the cell type involved in the process of RLIP76-
mediated PHE extrusion we compared 14C-PHE transport
in vesicles obtained from endothelial cells and astrocytes
isolated and cultured from either control (n = 4) or epilep-
tic (n = 6) brain [31] (Fig. 3c, d). PHE transport was sig-
nificantly higher in endothelial cells as compared to
astrocytes, and greater in both cell types from epileptic tis-
sues. These data are in agreement with the immunocyto-
chemical results showing predominant expression of
RLIP76 in human epileptic endothelial cells and not brain
parenchymal cells.
PHE has been described as an MDR1 substrate based on
experiments performed on knock out mice lacking Pgp
[32]. We performed experiments in RLIP76+/+ and RLIP76-
/- C57B mice injected i.p. with PHE (33 or 83 mg/kg, 6 ani-
mals per group; Fig. 3e). At both doses, brain PHE levels
were higher in RLIP76-/- mice as compared with RLIP76+/+
(p < 0.05). However, this was more prominent at the 83
mg/kg level. A statistically significant increase in PHE
accumulation in brain was observed at both concentra-
tions (Fig. 3f). RLIP76-/- mice were characterized by higher
levels of PHE in both brain and serum compared with the
wild-type, consistent with a role of RLIP76 in renal excre-
tion of PHE (not shown). To account for this, a group ofBMC Neuroscience 2005, 6:61 http://www.biomedcentral.com/1471-2202/6/61
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Phenytoin Transport by RLIP76 Figure 2
Phenytoin Transport by RLIP76. A) Requirement of both ATP and RLIP76 for increased liposomal uptake of 14C-PHE. 
Experiments in a-e were performed four times and triplicate determinations were performed for each data point. B) Time 
dependent uptake of 14C-PHE and 14C-CBZ by RLIP76-proteoliposomes in the presence of ATP. Data were fitted by y = 
y0+A1e(-x/t). C) Saturable kinetics of 14C-PHE and 14C-CBZ transport by purified recombinant human RLIP76 with respect to 
ATP concentrations. Data were fitted by a single exponential. D) Transport of PHE and CBZ by RLIP76-proteoliposomes. 
Radiolabeled drugs were incubated in the absence or presence of 4 mM ATP with RLIP76 liposomes containing variable 
amounts of RLIP76. Unless both ATP and RLIP76 were present, drug-uptake was close to the detection limit. Data points were 
fitted by a Sigmoid y = A2 + (A1-A2)/(1 + exp(x-x0)/dx). E) Determination of Km values for RLIP76-mediated transport of 14C-
PHE and 14C-CBZ. F) RLIP76 mRNA expression in normal (aneurysm, HUVEC) and "epileptic" endothelial cells isolated from 
tissue resections [31,34]. Note that RLIP76 was significantly (p < 0.05) increased in endothelial cells isolated from multiple drug 
resistant patients (n = 6) compared to control tissue (n = 8). G) Analysis of specimens by Western-blot analysis confirmed 
these findings. We compared protein expression in dysplastic or normal cortex within the same patient [42,43]. Note that the 
actively epileptic cortex was characterized by gross abnormality and increased expression of RLIP76. The Coomassie stained 
band shows the migration pattern of purified human RLIP76 to emphasize the increased levels of signal in both bands. The 
arrows point to histological sections from the same regions used to isolate protein. Note that abnormal clustering of cells is evi-
dent on H&E stained sections and in neighboring samples stained with DAPI. The bars indicate 100 µm; the dotted and dashed 
lines show the extent of abnormal nuclear clustering while the asterisks refer to abnormal vascular structure present in these 
grossly malformed cortices. H) RLIP76 is up-regulated in epileptic brain and RLIP76 protein expression levels correlate with 
transport activity in inside-out membrane vesicles prepared from the same tissues. Data were fitted linearly (R value of 0.99).BMC Neuroscience 2005, 6:61 http://www.biomedcentral.com/1471-2202/6/61
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wild-type animals was injected with elevated (4166 mg/
kg) doses of PHE to achieve serum levels comparable to
those seen in knock out animals injected with much lower
quantities (83 mg/kg). RLIP76-/-  mice demonstrated
greater neurotoxicity after administration of PHE; side
effects in these animals included lethargy and status-epi-
lepticus (Fig. 3g).
Conclusion
Taken together, our results show that RLIP76 is an impor-
tant PHE and CBZ transporter at the human blood brain
barrier, and its expression is increased in the BBB from
patients with drug-resistant epilepsy. RLIP76 fulfilled
many of the predicted properties for a mediator of CNS
pharmacoresistance, including: 1) presence at the ana-
tomical interface between brain and blood; 2) transport of
the antiepileptic drugs PHE and CBZ; 3) functional
expression in brain microvascular endothelial cells but
not in parenchymal glia or neurons; and 4) increased CNS
accumulation of PHE in RLIP76-/- mice. These results also
demonstrate for the first time that the putative mediator
of multiple drug resistance in epilepsy, MDR1 [33], is in
fact overshadowed in potency by another ATP-dependent
transporter. Our results are also in accord with previous
reports which questioned the relevance of MDR1 as a
multiple drug resistance mechanism, while rather suggest-
ing a role in neuroglial protection [10]. We also confirmed
that CBZ is a poor MDR1 substrate [34].
Several important questions remain unanswered. For
example, is the widespread distribution of MDR1, MRPs
(in particular MRP2 [35]) and RLIP76 in epileptic brain
also linked to the pathology itself? Are these transporters
expressed as a response to a hostile environment or are
they regulated exclusively by chemotherapy? Both MDR1
and MRP are involved in cell survival, and recent evidence
by this laboratory [8-10] have shown that apoptotic
mechanisms are lacking in epileptic brain. Interestingly,
the original proposed role for RLIP76 was indeed that of
a molecule involved in detoxification or protection of
cells living in hostile environments [36,37]. More
recently, Yadav et al. have confirmed a dual role for
Phenytoin transport in epileptic brain is mediated by RLIP76 Figure 3
Phenytoin transport in epileptic brain is mediated by RLIP76. A-B) Relative contribution of RLIP76 and MDR1 to 
total AED transport capacity in IOV prepared from brain tissue of non-epileptic, non-multiple drug resistant and multiple drug 
resistant epileptic patients. This was determined using anti-RLIP76 and anti-MDR1 antibodies [23,25]. In this figure, * and ** 
represent p < 0.05 and 0.01 respectively. C-D) Time dependent PHE uptake by IOV prepared from primary cultures of astro-
cytes or endothelial cells from normal (diamonds) or epileptic brain (squares). E-F) Brain PHE levels in RLIP76+/+ and RLIP76-/- 
mice 2 h after IP administration of Phosphenytoin at 33 or 83 mg/kg (3 animals/group). G) After exposure to the antiepileptic 
drug, RLIP76+/+ animals (left panel) appeared relatively unaffected compared with RLIP76-/- mice (right panel) where a severe 
neurological toxicity including extensor posturing, lethargy and status epilepticus were observed.BMC Neuroscience 2005, 6:61 http://www.biomedcentral.com/1471-2202/6/61
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RLIP76, consisting of anti-apoptotic and drug resistance
functions [38]. Thus, purely on the bases of overall
function, MDR1 and RLIP76 are indistinguishable. It is
possible that multiple drug resistance molecules, in addi-
tion to cooperating in drug extrusion, also play a role in
the control of cellular homeostasis.
In conclusion, we report a novel, non-ABC transporter
mediated mechanism of antiepileptic drug resistance that
may synergistically cooperate with MDR1. The relative
contribution of each transporter as determined in vitro
and ex situ suggests a predominant role for RLIP76. Our
results are consistent with a predominant role of the
Table 1: Human Tissue Donor Information
ID Age Sex Notes AED failed Use
1 0.8 M EPi- Hemispherectomy None WB
2 0.3 M Epi-Hemispherectomy Ketogenic Diet WB, AED transport studies
3 57 F Temporal Lobe Epilepsy PHE, CBZ,TPM WB
4 33 F Control (AVM) None WB
5 61 F Temporal Lobe epilepsy VAL,CBZ,TPB WB, AED transport studies
6 30 M Control Parasaggital Cist None WB, AED transport studies
7 0.9 F Frontal/Parietal Epilepsy VAL, PBT, TPM WB
8 14 M Temporal Lobe Epilepsy CBZ, Keppra, PBT,TPM, VAL WB
9 42 M Temporal Lobe Epilepsy VAL, PBT, primidone, tiagabine, AED transport studies
10 27 F Temporal Lobe Epilepsy PHE,VAL,gabapentin,CBZ, TPM AED transport studies
11 7 M R. Lateral Parietal/Occipital/Temporal Lobes PBT, PHE, TPM, CBZ, DZP, LMT AED transport studies
12 14 M Temporal Lobe Epilepsy VAL,Keppra, CBZ, other AED transport studies
13 31 F Temporal Lobe Epilepsy gabapentin, CBZ,VAL,PHE,PBT AED transport studies
14 60 F Temporal Lobe Epilepsy PBT, MBL, TGL, DPT, VLM, MSL, FBT In vitro cells AED
15 43 F Focal Epi N/A In vitro cells AED
16 56 M Focal Epi PHE, PBT, CBZ, VAL, ETS In vitro cells AED
17 43 F Temporal Lobe Epilepsy PHE, CBZ, VAL, GBP mRNA analysis
18 40 F Control (Aneurysm) NONE mRNA analysis
20 58 F Focal Epi PHE, PBT, VAL, PRM, FBT, GBP, TPM mRNA analysis
21 35 M Temporal Lobe Epilepsy PHE, CBZ, VAL, PRM, VGB mRNA analysis
22 28 M Temporal Lobe Epilepsy PHE, PBT, CBZ, VAL, TPM, CZP, GBP mRNA analysis
23 38 M Temporal Lobe Epilepsy PHE, CBZ, VAL, FBM, GBP mRNA analysis
24 39 M Temporal Lobe Epilepsy PHE, PBT, VAL, PRM, MSD mRNA analysis
25 31 M Temporal Lobe Epilepsy PHE, PBT, VAL, TPM mRNA analysis
26 23 M Temporal Lobe Epilepsy PHE, PBT, CBZ, VAL, GBP mRNA analysis
27 45 F Control (Aneurysm) NONE mRNA analysis
28 22 F Control (Aneurysm) NONE mRNA analysis
36 7 M Temporal Lobe Epilepsy PHE, CBZ, VAL, GBP ICC
37 28 F Temporal Lobe Epilepsy PHE, PBT, CBZ, VAL ICC
38 7 M Temporal Lobe Epilepsy ? ICC
39 4 F Frontal and Parietal Epilepsy PHE, CBZ, VAL, PRM, ICC
40 8 F Temporal lobe epilepsy CBZ, PHE, VAL ICC
41 24 M Control (AVM) NONE ICC
42 1 M Frontal Epilepsy CBZ, PHE, VAL ICC
43 25 M Temporal Lobe Epilepsy Phe CBZ ICC
44 1 M Hemispherectomy None ICC
45 23 F Contol (AVM) None ICC
46 23 M Temporal lobe epilepsy gabapentin, CBZ,VAL,PHE, ICC
47 23 M Control (AVM) None ICC
48 7 M TSC ? ICC
49 3 F Epilepsy Right Hemi ? ICC
50 Autopsy ICC
51 Autopsy ICC
52 Autopsy ICC
53 Autopsy ICC
54 Autopsy ICC,WB
55 Autopsy ICC,WBBMC Neuroscience 2005, 6:61 http://www.biomedcentral.com/1471-2202/6/61
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blood-brain barrier in determining multiple drug resist-
ance to antiepileptic drugs.
Methods
Reagents
CNBr-activated Sepharose 4B, 1-chloro-2,4-dinitroben-
zene (CDNB), PMSF, β-mercaptoethanol (BME), EGTA,
EDTA, ATP, butylated hydroxytoluene (BHT), and polido-
canol (C12E9), were purchased from Sigma Chemical Co.,
St. Louis, MO. DE-52 (diethylaminoethyl cellulose) anion
exchanger was purchased from Whatman International
Ltd. Maidstone, England. Bio-Beads (SM-2 adsorbent)
and Chelex-100 resin were purchased from Bio-Rad Labo-
ratories (Hercules, CA). Tryptone and yeast extract for pre-
paring culture media were purchased from DIFCO
laboratories, Detroit, MI. PHE was purchased from Pfizer
New York, NY. [4-14C]-5,5-diphenylhydantoin (specific
activity 49.37 mCi/mmol) and [14C]-CBZ (specific activity
22.6 mCi/mmol) were purchased from Perkin Elmer Life
Sciences, Boston, MA and Sigma Chemical Co., St. Louis,
MO, respectively. Source of anti-RLIP76 IgG used in these
studies was the same as previously described [39]. DNP-
SG and DNP-SG-Sepharose-4B affinity resin were pre-
pared as previously described [39].
Tissue procurement and inside-out vesicle preparation 
(IOV)
Human subjects (see Table 1 for details) were used for
these studies as donors of tissue samples. The investiga-
tion conforms to the principles outlined in the Declara-
tion of Helsinki. For freshly isolated surgical samples,
patient consent was obtained as per the Institutional
Review Board instructions before collection of the speci-
mens; autopsy materials were obtained from organ
donors. Endothelial cells and glia were isolated from
brain specimens from patients undergoing a temporal
lobectomy to relieve medically intractable seizures (n =
12) or cortices of patients undergoing surgery for removal
of vascular malformations (n = 3). Tissue from autopsy
material was used for Fig. 1a. Blood vessels were isolated
from resected tissue by manually pulling out a combina-
tion of penetrating pial and superficial pial vessels. The
methods are described in detail elsewhere [9,34]. The
plasma membrane vesicles of human brain cells were pre-
pared as described elsewhere [21,23,25]. Briefly, the cells
were separated form the suspension buffer by centrifuga-
tion and lysed by incubation in hypotonic buffer (0.5 mM
sodium phosphate, pH 7.0, containing 0.1 mM EDTA and
0.1 mM PMSF for 1.5 h, followed by homogenization.
After centrifugation of the homogenate at 12,000g (10
min at 4°C), the postnuclear supernatant was further cen-
trifuged at 100,000g for 40 min at 4°C. The resulting pel-
let was suspended in the reconstitution buffer (250 mM
sucrose-10 mM Tris-HCl, pH 7.4) homogenized with tight
fitting Dounce homogenizer and layered over 38%
sucrose in 5 mM Hepes-KOH, pH 7.4. After centrifugation
at 28,000g for 2 h at 4°C the interphases were collected,
washed by centrifugation in the reconstitution buffer
(100,000g), and passed 20 times through a 27-gauge nee-
dle for vesicle formation.
Anti-RLIP76 and anti-MDR1 antibodies
Goat-anti-human Pgp antibody C-19 was purchased from
Santa Cruz Biotech, CA. Polyclonal rabbit-anti-RLIP76
IgG as well as pre-immune IgG were prepared and purified
as described previously [39,40]. Briefly, recombinant
human RLIP76 expressed in E. coli and purified by DNP-
SG-Sepharose affinity purification as previously described
[39] was injected (75 µg) into New Zealand White rabbit
after obtaining preimmune serum. After booster doses of
50 µg each at two week intervals, post-immune serum was
obtained. The IgG fraction from pre- and post-immu-
nized, heat-inactivated serum was purified by DE-52
anion exchange chromatography, followed by protein-A-
Sepharose affinity chromatography. The purity of the anti-
body was checked by SDS-PAGE as well as Western blot-
ting against goat anti-rabbit IgG. Aliquots of the antibody
were stored at -86°C and checked regularly by aerobic and
anaerobic cultures for contamination. The specificity of
anti-RLIP76 and other antibodies has been stringently
established: purified recombinant RLIP76 used for raising
polyclonal antibodies was demonstrated to be homoge-
nous by amino acid composition analysis demonstrating
amino acid yields within 96% of those expected according
to its sequence SELDI-MS demonstrating a pattern of
[M+H] peaks consistent with homogenous preparations
of RLIP76 [39].
Immunocytochemistry
To investigate the expression of RLIP76 protein and its
localization in both various human tissues and in human
epileptic brain, slide mounted sections of 10 µm thickness
from frozen brain tissue were labeled as previously
described [8,9]. Purified anti-RLIP76 IgG was used as pri-
mary antibody. FITC conjugated purified donkey anti-rab-
bit IgG (Jackson Immunoresearch Laboratories, West
Grove, Pennsylvania) was the secondary antibody.
Preparation of liposomes containing purified recombinant 
RLIP76
The 1968 bp full length open reading frame cDNA of
human RLIP76 was cloned from a λgt11 human bone
marrow library by immuno-screening, using anti-DNP-SG
ATPase antibodies and was subcloned into the prokaryo-
tic expression vector, pET30a(+) (Novagen, Madison,
Wisconsin), creating the pET30-RLIP76 plasmid free of
extraneous sequences. This plasmid was transformed into
E. coli BL21 (DE3). Protein was expressed in E. coli BL21
(DE3) grown at 30°C after induction with 0.4 mM IPTG
[39]. DNP-SG affinity chromatography was used asBMC Neuroscience 2005, 6:61 http://www.biomedcentral.com/1471-2202/6/61
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described previously [39,40] to obtain purified RLIP76.
ATPase activity was performed as previously described to
monitor purification [26]. Purity was checked by SDS-
PAGE, Western blot analysis and amino acid composition
analysis as previously described [39]. Purified protein was
dialyzed against liposome reconstitution buffer (10 mM
Tris-HCl, pH 7.4, 2 mM MgCl2, 1 mM EGTA, 100 mM
KCl, 40 mM sucrose, 2.8 mM BME, 0.05 mM BHT, and
0.025% polidocanol). An aqueous emulsion of soybean
asolectin (40 mg/ml) and cholesterol (10 mg/ml) was
prepared in the reconstitution buffer by sonication. This
emulsion was diluted 10 fold by addition of dialyzed
RLIP76 in reconstitution buffer to achieve a final RLIP76
concentration of 0.1 mg/ml. The reaction mixture was
sonicated at 15 s at 50 W. Vesiculation was initiated by
addition of SM-2 Bio-beads (200 mg/ml) pre-equilibrated
in the reconstitution buffer (without polidocanol). Vesic-
ulation was carried out for 4 h at 4°C, followed by
removal of SM-2 Bio-beads by centrifugation. The vesicles
were collected and analyzed for protein content, transport
activity, and microbial contamination. Control vesicles to
measure non-specific transport, were prepared using an
equal amount of crude protein from E. coli not expressing
RLIP76.
Transport studies
For transport studies, crude membrane inside-out vesicles
(IOV) were prepared from different brain tissues and cells
by the method as previously described [23,25]. Briefly,
stock solutions of 40 mM MgCl2 and 40 mM of ATP were
prepared in buffer containing 40 mM sucrose and 10 mM
Tris-HCl, pH 7.4. The reaction mixture (120 µL) consisted
of IOV protein (80 µg), 10 mM Tris-HCl, pH 7.4, 40 mM
sucrose, 4 mM MgCl2 and appropriate volume of radio-
labeled 14C-PHE and 14C-CBZ were added to attain a final
concentration of 1 µM. To start the reaction, buffer with or
without ATP was added to achieve a final concentration of
0 or 4 mM ATP. The uptake was stopped by rapid filtration
of a fixed aliquot (30 µL) of the reaction mixture through
96 well nitrocellulose plates (0.45 µm pore size). After fil-
tration, the bottoms of the nitrocellulose membranes
were blotted dry with filter paper and punched out, and
the associated radioactivity was measured by placing in
liquid scintillation counting vials. Scintillation vials were
vortexed thoroughly, allowed standing for 1 h at room
temperature, and counted in a liquid scintillation counter.
Each determination was performed in triplicate. ATP-
dependent uptake of 14C-PHE and 14C-CBZ were deter-
mined by subtracting the radioactivity of the control with-
out ATP from that of the experimental containing ATP and
the transport was calculated in terms of pmol/min/mg
protein.
cDNA array and mRNA
The details of the tissue culture procedures and mRNA
extraction have been described previously [5]. Briefly, sur-
gically obtained specimens were washed in phosphate
buffered saline (PBS) and incubated in collagenase type II
(2 mg/ml, Worthington chemicals) at 37°C for 20 min to
dissociate the endothelial cells. Collagenase was then
washed off with the medium used for growing ECs (1.5 g/
100 ml, MCDB 105 supplemented with Endothelial Cell
Growth Supplement, 15 mg/100 ml, heparin 800 units/
100 ml, 10% fetal bovine serum, and penicillin/strepto-
mycin 1%, Sigma chemicals), and ECs were harvested
using a sterile cotton swab soaked in the medium. EC
stained positive for Von Willebrand factor and were nega-
tive for glial fibrillary acidic protein. ECs were purged
from the culture dishes by gentle enzymatic dissociation
(collagenase) and collected by centrifugation. Equal
amounts of the pellet were used for total RNA isolation
and protein extraction. Total RNA was extracted with the
Trizol reagent (Gibco Labs). Integrity of the isolated RNA
was confirmed by agarose formaldehyde gels. For gene
expression analysis, human GENEFILTERS™ (Research
Genetics Inc., Huntsville, Alabama) were used for this
study. Each filter membrane contains approximately
4,000 known human genes. 33P-dCTP was used to label
probe used for hybridization to produce clean and sharp
signals, as recommended by the manufacturer.
RLIP76 knockout animals
RLIP76+/- heterozygous knockout animals were commis-
sioned from Lexicon genetics, and prepared by the strat-
egy described previously [41]. Briefly, C57B mice (12 wk
old), born of RLIP76+/- × RLIP76+/- mating, were geno-
typed by PCR strategy. We generated C57B mice which
carry heterozygous (+/-) or homozygous (-/-) disruption
of the RLIP76 gene, and established colonies of RLIP76+/
+, RLIP76+/-, and RLIP76-/- C57B mice by segregation
and mating of animals based on genotyping by polymer-
ase chain reaction (PCR) on tail DNA. Western-blot anal-
ysis of mouse tissues using anti-RLIP76 antibodies
confirmed decreased RLIP76 levels in the RLIP76+/-
mouse, and its absence in tissues from the RLIP76-/-
mouse [41]. Consistent with the observed function of
RLIP76 as a transporter of GS-E and doxorubicin (DOX)
in cell culture studies [23,25], GS-E and DOX transport in
membrane vesicles was decreased in a stepwise fashion
from the RLIP76+/+, to RLIP76+/-, to RLIP76-/- mice [41].
Measurement of PHE concentration in wild type and 
RLIP76 knockout mouse serum and brain tissues
Twelve week old C57B mice born of heterozygous × het-
erozygous mating were genotyped by PCR on mouse tail
DNA using forward, reverse and LTR primers [41]. PHE
measurements were performed on 5 wild type (RLIP76+/+)
and 5 RLIP76 knockout (RLIP76-/-) animals sacrificed 2 hBMC Neuroscience 2005, 6:61 http://www.biomedcentral.com/1471-2202/6/61
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after a single i.p.-injection of phosphenytoin or PHE. A
10% homogenate of mouse brain tissues was prepared
and centrifuged at 28,000 × g for 45 min at 4°C. PHE lev-
els in homogenate and plasma was measured using the
Dade Behring Clinical Multichannel Analyzer with the
PHE Flex® reagent cartridge, a method based on PETINIA
technology.
Abbreviations used
RALBP1, official human genome designation for human
Ral-binding protein-1, synonymous with RALBP1, and
homologous to rat RALBP1 and mouse RIP1. We refer to
the mouse, rat and human proteins as RLIP76 in the
present communication; AED, anti-epileptic drug; BBB,
blood-brain barrier; CBZ, carbamazepine; EC, endothelial
cells; GSH, glutathione; GS-E, glutathione electrophile
conjugates; DOX, doxorubicin; MCDB, modified Czapek
Dox broth; PHE, phenytoin.
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